Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDG1901 vs Ozempic (Novo Nordisk semaglutide) in type 2 diabetes on metformin
CTR20232286Phase 3Completed
- Sponsor
- Chongqing Paijin Biotechnology
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide biosimilar (HDG1901) in type 2 diabetes mellitus (T2DM), sponsored by Chongqing Paijin Biotechnology. Started Aug 2023; status: completed.
02
Drugs
semaglutide biosimilar (HDG1901)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20232286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232286.